Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

Objective. To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen. Methods. A total of 60 newly diagnosed MM patients were anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shenghao, Zheng, Cuiping, Chen, Songyan, Cai, Xiaoping, Shi, Yuejian, Lin, Bijing, Chen, Yuemiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575715/
https://www.ncbi.nlm.nih.gov/pubmed/26425561
http://dx.doi.org/10.1155/2015/927105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575715/
https://www.ncbi.nlm.nih.gov/pubmed/26425561
http://dx.doi.org/10.1155/2015/927105

Ejemplares similares